CCM
CABA icon

Coldstream Capital Management’s Cabaletta Bio CABA Stock Holding History

Coldstream Capital Management’s Portfolio CABA Stock Details CABA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-280
Closed -$388 – 1464
2025
Q1 		$388 Buy
+280
New +$597 ﹤0.01% 3404

Other funds holding CABA

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $359M AUM 7.93% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

Coldstream Capital Management's CABA Position: Q2 2025 in Review

Coldstream Capital Management sold out of Cabaletta Bio (CABA) in Q2 2025, closing a stake of 280 shares — an estimated $388 sold.

Coldstream Capital Management first reported a position in CABA in Q1 2025 and held it in 1 quarter. The position peaked at $388 in Q1 2025. 86 funds tracked by Wall St. Rank hold CABA as of Q2 2025.

  • Coldstream Capital Management reported no remaining Cabaletta Bio position as of Q2 2025 after selling out during the quarter.
  • Coldstream Capital Management sold 280 Cabaletta Bio shares in Q2 2025, an estimated $388.
  • Coldstream Capital Management first reported a position in Cabaletta Bio in Q1 2025 and held it in 1 quarter.
  • Coldstream Capital Management's Cabaletta Bio position peaked at $388 in Q1 2025.
  • 86 funds tracked by Wall St. Rank held Cabaletta Bio as of Q2 2025.

Based on Coldstream Capital Management's 13F filing for Q2 2025, filed 12 Aug 2025.